PPT-Randomisation: part 2

Research supported by TLRI Experiments amp the Randomisation Test The difference between two means Watch out for The chance is acting alone explanation How we assess the plausibility . Standard Operating Procedure 9 Randomisation and Blinding Page 1 of 9 Effective: 6 August 2012 Version 1.3 Randomisation and Blinding Version 1. 3 Effective date: 6 August 2012 Author: Claire Daffe PGDip. MRCGP. GP and Clinical Lecturer. Honorary Fellow at The Centre for Evidence Based Medicine. University of Oxford . R. andomised. . controlled trials. PEBM. 2013. Warm up quiz…... Apple . inc.. 4http://www.ific.org,http://www.cfsan.fda.gov/˜dms/foodic.html5http://www.google.com patternfreq. part inftheg? whole 488 part forfuseinjmakingg? whole 129 part -fortied whole 74 part from whole Double - blind 90% Power N=324 Study Design: Dose Ranging Phase 2b 6 months follow Chloroquine # + 15mg Primaquine + Days 2 - 15 (n=54) Chloroquine # Days 1 - 3 (n=54) Chloroquine # + 300mg Tafe Carl Hamblyn. SO_P. S_AR. Designing an Experiment. An experiment is a set of observations made under conditioned controlled by the observer. Experiments allow us to claim cause and effect (if correctly designed). *. 1:1. Open-label. ≥ 18 years. HCV genotype 4. HCV RNA ≥ 1 000 IU/mL. Naïve or pre-treated with PEG-IFN + RBV Compensated cirrhosis ** . No HBV or HIV co-infection. N = 59. W12. OPV/PTV/r + RBV. Open-label. 18-70 years. HCV genotype 1. Naïve or null-response . to PEG-IFN + RBV. HCV RNA > 10 000 IU. /ml. No HBV or HIV coinfection. Design. N = 34. W8. Objective. SVR. 12. (HCV RNA < . 25 IU. N = 100. W12. W24. Arm B: . compensated cirrhosis. N = 31. N = 29. Arm C:. compensated cirrhosis. Arm A: . No cirrhosis. AGATE-II Study: OBV/PTV/r + RBV in genotype 4 Egyptian patients without or with cirrhosis . Open-label. 18-70 . years. HCV genotype 1. Naïve or null-response . to PEG-IFN + RBV. HCV RNA > 10,000 IU/ml. No cirrhosis . No . HBV or . HIV . co-infection. Design. N = . 39. W12. N = . 40. O. bjective. ≥ 18 years. HCV genotype 3. Treatment-naïve . HCV RNA > 1 000 IU/mL. No cirrhosis **. No HBV co-infection. No HIV co-infection. ENDURANCE-3 Study: . glecaprevir. /. pibrentasvir. . vs SOF DCV in genotype 3 without cirrhosis. Childhood. Orla Doyle . (. UCD School of Economics & UCD Geary Institute). Conference . on Irish Economic Policy. 1. st. February 2013. Importance of Early Childhood Investment. Targeted early intervention programmes effective way of reducing socio-economic inequalities in children’s skills . atelectasis. .. the RECOVERY trial. Second Randomisation. IL-6 and . Tocilizumab. IL-6. binds surface receptor. IL-6. binds soluble receptor. IL-6/IL-6R complex binds gp130 on cell surface. IL-6/IL-6R/gp130 complex activates JAK1/2-STAT1/3 signalling. Adrian Boyle. Suturing versus conservative management of lacerations of the hand: randomised controlled trial. BMJ. What did they do? PICO. Population. Consecutive (11am-11pm) patients with hand lacerations less than 2cm long.